Clin Nucl Med 2021 Jun 10. Epub 2021 Jun 10.
From the Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite Claude Bernard Lyon 1 University, Lyon Departments of Nuclear Medicine Critical Care Pharmacy Haematology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite INSERM U1052 and CNRS UMR5286, Lyon Cancer Research Center, Lyon Department of Biology and Therapy, Etablissement Français du Sang Auvergne-Rhône-Alpes Department of Haematology, Grenoble University Hospital, Grenoble Department of Haematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne Department of Haematology, Centre Léon Bérard, Lyon Department of Haematology, Groupe Hospitalier Mutualiste, Institut Daniel Hollard, Grenoble Department of Haematology, Clermont Ferrand University Hospital, Clermont Ferrand, France.
Purpose Of The Report: We aimed to evaluate the role of 18F-FDG PET/CT in predicting patient outcome following chimeric antigen receptor T (CAR T) cells infusion in aggressive B-cell lymphoma.
Methods: 18F-FDG PET/CT data before leukapheresis, before CAR T-cell infusion and 1 month (M1) after CAR T-cell infusion, from 72 patients were retrospectively analyzed. SUVmax, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and parameters describing tumor kinetics were calculated for each 18F-FDG PET/CT performed. Read More